Next, to assess the potential for tumor-specific targeting of BCL-XL in vivo, we implanted sgControl (non-targeting) and sgBCL2L1 (BCL-XL KO) PaTu-8902 cells in NOG mice and treated with vehicle or BQ. This evidence concerns the gene BCL2L1 and neoplasm.